Three dose regimens of fulvestrant in postmenopausal Japanese women with advanced breast cancer: results from a double-blind, phase II comparative study (FINDER1)
Authors:
Open Access
- 21 May 2010
- journal article
- research article
- Published by Elsevier in Annals of Oncology
- Vol. 21 (12) , 2342-2347
Abstract
Background: FINDER1 compared efficacy, tolerability and pharmacokinetics (PK) of three fulvestrant dose regimens in postmenopausal Japanese women with estrogen receptor (ER)-positive locally advanced/metastatic breast cancer recurring or progressing after prior endocrine therapy. Patients and methods: The primary end point of this randomised, multicentre, phase II study was objective response rate (ORR) and the secondary end points included time to progression (TTP), clinical benefit rate (CBR), PK profiles and tolerability. Postmenopausal women with ER-positive advanced breast cancer were randomised to 28-day cycles of fulvestrant approved dose (AD), loading dose (LD) or high dose (HD) until disease progression. Results: Hundred and forty-three patients (median age 61 years) received fulvestrant AD (n = 45), LD (n = 51) or HD (n = 47). ORR was similar across dose regimens: 11.1%, 17.6% and 10.6% for AD, LD and HD, respectively, with overlapping confidence intervals. TTP and CBR were also similar between groups (median TTP: 6.0, 7.5 and 6.0 months, respectively; CBR: 42.2%, 54.9% and 46.8% for AD, LD and HD, respectively). Cmax and area under the plasma concentration-time curve were dose proportional and PK steady state was reached earlier with LD and HD than with AD. All three doses were well tolerated, with a similar adverse-event profile and no emerging safety concerns. Conclusion: Fulvestrant AD, LD and HD had similar efficacy and tolerability profiles in postmenopausal Japanese women with ER-positive advanced breast cancer.Keywords
Funding Information
- AstraZeneca
This publication has 13 references indexed in Scilit:
- Pharmacokinetic profile of fulvestrant 500 mg vs 250 mg: Results from the NEWEST studyJournal of Clinical Oncology, 2008
- Double-Blind, Randomized Placebo Controlled Trial of Fulvestrant Compared With Exemestane After Prior Nonsteroidal Aromatase Inhibitor Therapy in Postmenopausal Women With Hormone Receptor–Positive, Advanced Breast Cancer: Results From EFECTJournal of Clinical Oncology, 2008
- Fulvestrant (Faslodex®)—How to Make a Good Drug BetterThe Oncologist, 2007
- Fulvestrant (‘Faslodex’): Current and future role in breast cancer managementCritical Reviews in Oncology/Hematology, 2006
- Fulvestrant versus anastrozole for the treatment of advanced breast carcinomaCancer, 2005
- Fulvestrant versus anastrozole for the treatment of advanced breast carcinoma in postmenopausal womenCancer, 2003
- A phase I trial to assess the pharmacology of the new oestrogen receptor antagonist fulvestrant on the endometrium in healthy postmenopausal volunteersBritish Journal of Cancer, 2002
- Double-Blind, Randomized Trial Comparing the Efficacy and Tolerability of Fulvestrant Versus Anastrozole in Postmenopausal Women With Advanced Breast Cancer Progressing on Prior Endocrine Therapy: Results of a North American TrialJournal of Clinical Oncology, 2002
- Fulvestrant, Formerly ICI 182,780, Is as Effective as Anastrozole in Postmenopausal Women With Advanced Breast Cancer Progressing After Prior Endocrine TreatmentJournal of Clinical Oncology, 2002
- Similarities and distinctions in the mode of action of different classes of antioestrogens.Endocrine-Related Cancer, 2000